Want to see GB:GSK full AI Analyst Report?

GlaxoSmithKline (GSK) Share Forecast & Price Target

1,151 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GSK Analyst Ratings

Hold

3 Buy

10 Hold

2 Sell

Based on 15 analysts giving stock ratings to

GlaxoSmithKline

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GSK Stock 12 Month Forecast

Average Price Target

2,103.00 p

▼(-1.91% Downside)

Based on 15 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is 2,103.00 p with a high forecast of 2,630.00 p and a low forecast of 1,700.00 p. The average price target represents a -1.91% change from the last price of 2,144.00 p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1344":"1,344 p","2631":"2,631 p","1665.75":"1,665.8 p","1987.5":"1,987.5 p","2309.25":"2,309.3 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2630,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.63K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.10K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.70K </span>\n  </div></div>","useHTML":true}}],"tickPositions":[1344,1665.75,1987.5,2309.25,2631],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1930,1983.8461538461538,2037.6923076923076,2091.5384615384614,2145.3846153846152,2199.230769230769,2253.076923076923,2306.923076923077,2360.769230769231,2414.6153846153848,2468.4615384615386,2522.3076923076924,2576.153846153846,{"y":2630,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1930,1943.3076923076924,1956.6153846153845,1969.923076923077,1983.2307692307693,1996.5384615384614,2009.8461538461538,2023.1538461538462,2036.4615384615386,2049.769230769231,2063.076923076923,2076.3846153846152,2089.6923076923076,{"y":2103,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1930,1912.3076923076924,1894.6153846153845,1876.923076923077,1859.2307692307693,1841.5384615384614,1823.8461538461538,1806.1538461538462,1788.4615384615386,1770.7692307692307,1753.076923076923,1735.3846153846152,1717.6923076923076,{"y":1700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1361.126,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1345.708,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1410.581,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1628.868,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1735.088,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1769.618,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1793.704,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1892.508,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2160.349,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2088.008,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 21</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1883.864,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1842.5,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1930,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target2,630 p

Average Price Target2,103 p

Lowest Price Target1,700 p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Gordon CFA

Barclays

1,900 p

Sell

-11.38%

Downside

Reiterated

07/14/26

Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

Matthew Weston

UBS

1,940 p

Hold

-9.51%

Downside

Reiterated

07/13/26

UBS Remains a Hold on GlaxoSmithKline (GSK)

Zain Ebrahim

J.P. Morgan

1,700 p

Sell

-20.71%

Downside

Reiterated

07/13/26

J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

07/09/26

Guggenheim Remains a Hold on GlaxoSmithKline (GSK)

Emmanuel Papadakis

Deutsche Bank

1,900 p→1,950 p

Hold

-9.05%

Downside

Reiterated

07/09/26

Deutsche Bank Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

Rajesh Kumar

HSBC

1,500 p→1,860 p

Hold

-13.25%

Downside

Upgraded

07/06/26

GSK upgraded to Hold from Reduce at HSBCGSK upgraded to Hold from Reduce at HSBC

Rajan Sharma

Goldman Sachs

1,870 p→1,890 p

Hold

-11.85%

Downside

Reiterated

06/30/26

Goldman Sachs Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

Sachin Jain

Bank of America Securities

2,350 p

Hold

9.61%

Upside

Reiterated

06/30/26

GSK: Neutral Stance Maintained as Near-Term Strength Offsets Pipeline and Litigation Risks; Price Target Held at £2,350

Justin Smith

Bernstein

2,630 p

Buy

22.67%

Upside

Reiterated

06/23/26

Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)

Unknown Analyst

Intron Health

Not Ranked

Intron Health

2,000 p

Hold

-6.72%

Downside

Upgraded

06/10/26

GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health

Michael Leuchten

Jefferies

2,500 p

Buy

16.60%

Upside

Reiterated

06/03/26

GlaxoSmithKline (GSK) Gets a Buy from Jefferies

Graham Parry

Citi

―

Hold

―

Reiterated

05/29/26

Analysts Conflicted on These Healthcare Names: GlaxoSmithKline (LSE: GB:GSK) and C4 Therapeutics (NASDAQ: CCCC)

Nicolas Pauillac

Kepler Capital

2,516 p

Buy

17.35%

Upside

Upgraded

05/26/26

Positive Report for GlaxoSmithKline (GSK) from Kepler Capital

Kerry Holford

Berenberg Bank

2,000 p

Hold

-6.72%

Downside

Reiterated

05/05/26

GlaxoSmithKline (GSK) Receives a Hold from Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

04/29/26

GlaxoSmithKline (GSK) Gets a Hold from DZ BANK AG

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Gordon CFA

Barclays

1,900 p

Sell

-11.38%

Downside

Reiterated

07/14/26

Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

Matthew Weston

UBS

1,940 p

Hold

-9.51%

Downside

Reiterated

07/13/26

UBS Remains a Hold on GlaxoSmithKline (GSK)

Zain Ebrahim

J.P. Morgan

1,700 p

Sell

-20.71%

Downside

Reiterated

07/13/26

J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

07/09/26

Guggenheim Remains a Hold on GlaxoSmithKline (GSK)

Emmanuel Papadakis

Deutsche Bank

1,900 p→1,950 p

Hold

-9.05%

Downside

Reiterated

07/09/26

Deutsche Bank Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

Rajesh Kumar

HSBC

1,500 p→1,860 p

Hold

-13.25%

Downside

Upgraded

07/06/26

GSK upgraded to Hold from Reduce at HSBCGSK upgraded to Hold from Reduce at HSBC

Rajan Sharma

Goldman Sachs

1,870 p→1,890 p

Hold

-11.85%

Downside

Reiterated

06/30/26

Goldman Sachs Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

Sachin Jain

Bank of America Securities

2,350 p

Hold

9.61%

Upside

Reiterated

06/30/26

GSK: Neutral Stance Maintained as Near-Term Strength Offsets Pipeline and Litigation Risks; Price Target Held at £2,350

Justin Smith

Bernstein

2,630 p

Buy

22.67%

Upside

Reiterated

06/23/26

Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)

Unknown Analyst

Intron Health

Not Ranked

Intron Health

2,000 p

Hold

-6.72%

Downside

Upgraded

06/10/26

GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health

Michael Leuchten

Jefferies

2,500 p

Buy

16.60%

Upside

Reiterated

06/03/26

GlaxoSmithKline (GSK) Gets a Buy from Jefferies

Graham Parry

Citi

―

Hold

―

Reiterated

05/29/26

Analysts Conflicted on These Healthcare Names: GlaxoSmithKline (LSE: GB:GSK) and C4 Therapeutics (NASDAQ: CCCC)

Nicolas Pauillac

Kepler Capital

2,516 p

Buy

17.35%

Upside

Upgraded

05/26/26

Positive Report for GlaxoSmithKline (GSK) from Kepler Capital

Kerry Holford

Berenberg Bank

2,000 p

Hold

-6.72%

Downside

Reiterated

05/05/26

GlaxoSmithKline (GSK) Receives a Hold from Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

04/29/26

GlaxoSmithKline (GSK) Gets a Hold from DZ BANK AG

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

3 Months

Justin SmithBernstein

Success Rate

12/20 ratings generated profit

Average Return

+2.46%

Copying Justin Smith's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.46% per trade.

1 Year

Michael LeuchtenJefferies

Success Rate

20/29 ratings generated profit

Average Return

+5.89%

Copying Michael Leuchten's trades and holding each position for 1 Year would result in 68.97% of your transactions generating a profit, with an average return of +5.89% per trade.

2 Years

Justin SmithBernstein

Success Rate

16/20 ratings generated profit

Average Return

+12.81%

Copying Justin Smith's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +12.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GSK Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GSK has received 6 Buy Ratings, 20 Hold Ratings, and 11 Sell Ratings. GSK average Analyst price target in the past 3 months is 2,103.00.

Each month's total comprises the sum of three months' worth of ratings.

GSK Financial Forecast

GSK Earnings Forecast

Next quarter’s earnings estimate for GSK is 0.46 p with a range of 0.41 p to 0.48 p. The previous quarter’s EPS was 0.47 p. GSK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year GSK has Performed in-line its overall industry.

GSK Sales Forecast

Next quarter’s sales forecast for GSK is 8.26B with a range of 8.07B to 8.36B . The previous quarter’s sales results were 7.63B . GSK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year GSK has Performed in-line its overall industry.

GSK Stock Forecast FAQ

What is GB:GSK’s average 12-month price target, according to analysts?

Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 2,103.00.

What is GB:GSK’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:GSK, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GlaxoSmithKline a Buy, Sell or Hold?

GlaxoSmithKline has a consensus rating of Hold, which is based on 3 buy ratings, 10 hold ratings and 2 sell ratings.

What is GlaxoSmithKline’s share price target?

The average share price target for GlaxoSmithKline is 2,103.00. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,630.00 p ,and the lowest forecast is 1,700.00 p. The average share price target represents -1.91% Decrease from the current price of 2,144 p.

What do analysts say about GlaxoSmithKline?

GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of GlaxoSmithKline?

To buy shares of GB:GSK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

GlaxoSmithKline (GSK) Share Forecast & Price Target

GSK Analyst Ratings

GSK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering GlaxoSmithKline

GSK Analyst Recommendation Trends

GSK Financial Forecast

GSK Earnings Forecast

GSK Sales Forecast

GSK Stock Forecast FAQ

Detailed List of Analyst Forecasts